CDK4/6抑制通过Rb依赖色素和转录基因重塑重新编程乳腺癌免疫皮组
Robin Minati1, Maxime Cahuzac2, Julie Perrault2
1Institute of Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada; Molecular Biology Program, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Cell reports
|December 14, 2025
概括
循环素依赖性激酶4/6抑制剂 (CDK4/6is) 通过增强主要基因相容性I类 (MHC I类) 呈现来重新编程瘤抗原格局. 这表明,将CDK4/6is与免疫疗法相结合可能会扩大乳腺癌中的抗原点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 循环素依赖性激酶4/6抑制剂 (CDK4/6is) 是转移性激素受体阳性 (HR+) 乳腺癌的标准治疗方法.
- 目前尚不完全了解CDK4/6的免疫调节作用.
研究的目的:
- 研究CDK4/6抑制对瘤抗原的免疫调节作用.
- 探索 CDK4/6 抑制引起的抗原呈现变化背后的机制.
主要方法:
- 利用多组学集成 (包括ATAC-seq) 来分析用Abemaciclib (一种CDK4/6抑制剂) 治疗的瘤细胞的变化.
- 研究了视网膜母细胞瘤蛋白 (Rb) 和BET蛋白在调解转录和染色质重编程中的作用.
- 鉴定和特征Abemaciclib诱导的MHC I类.
主要成果:
- 使用Abemaciclib的CDK4/6抑制增加了MHC I类表现,并重塑了HR+和三阴性乳腺癌细胞中的免疫组.
- 与Rb相关的转录和染色体重编程,包括H3K27的乙化和增强的染色体可访问性,推动了这些变化.
- 确定了新的免疫原性MHC I类,包括来自非编码区域的,增加瘤免疫性.
结论:
- 抑制CDK4/6在塑造瘤抗原性方面发挥着重要作用.
- 将CDK4/6is与免疫治疗结合起来,可能会扩大癌症治疗的抗原点范围.
关键词:
这是一种CDK4/6抑制剂.CP:癌症的癌症.CP: 免疫学 免疫学一个有着巨大的力量.乳腺癌 乳腺癌 乳腺癌癌症免疫疗法免疫疗法染色体重塑 染色体重塑 的方法免疫类药物 免疫类药物质谱测量质谱测量质谱测量质谱测量质量测量质谱测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量视网母细胞瘤蛋白质是什么瘤抗原是一种瘤抗原.更多相关视频
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
8.6K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.4K
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
01:23Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
01:20The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:39Positive Regulator Molecules
6.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K